US Patent

US12390475 — Dry powder treprostinil for the treatment of pulmonary hypertension

Formulation · Assigned to Liquidia Technologies Inc · Expires 2037-05-05 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dry powder inhalation treatment for pulmonary arterial hypertension containing at least 25 micrograms of treprostinil per capsule.

USPTO Abstract

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Drugs covered by this patent

Patent Metadata

Patent number
US12390475
Jurisdiction
US
Classification
Formulation
Expires
2037-05-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Liquidia Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.